Development and Characterization of an Anti-PD-L1 Immunotoxin for Targeted Cancer Therapy
This study provides a thorough characterization of the constructed IT, highlighting its potential as a therapeutic agent targeting PD-L1-expressing cancer cells. The results support the potential of this IT in cancer immunotherapy, emphasizing the need for further investigation into its efficacy and safety profiles.
Authors
- Mohammad Hosseininejad-Chafi
- Fatemeh Kazemi‐Lomedasht (ORCID: https://orcid.org/0000-0002-5832-1822)
- Akbar Oghalaie (ORCID: https://orcid.org/0000-0003-2135-8143)
- Mahdi Behdani (ORCID: https://orcid.org/0000-0002-4839-5123)
- Ali Takhteh
Institutions
- Pasteur Institute of Iran (IR)
- Islamic Azad University, Science and Research Branch (IR)
- Biotechnology Research Center (IR)
Publication Details
- Journal
- Current Pharmaceutical Biotechnology
- Published
- 2024-09-06
- DOI
- https://doi.org/10.2174/0113892010321088240823062243
- Citations
- 1
- Primary Topic
- Toxin Mechanisms and Immunotoxins
- Type
- article
- Field-Weighted Citation Impact
- 0.24